About: Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease
Creator	Sánchez, Melissa Assenmacher, \| Charles-Antoine Fox, Philip Fries, Ryan Larouche-Lebel, Éva Laughlin, Danielle Loughran, Kerry Oyama, Mark Solter, Phil
Source	PMC
abstract	BACKGROUND: Angiotensin‐converting enzyme 2 (ACE2) is a homologue of angiotensin‐converting enzyme (ACE) and produces angiotensin peptides (APs), such as angiotensin 1‐9 and 1‐7 that are vasodilatory and natriuretic, and act to counterbalance angiotensin II. HYPOTHESIS: Evidence of ACE2 can be found in tissues and plasma of dogs. Equilibrium concentrations of renin angiotensin aldosterone system (RAAS) APs differ in dogs with heart disease compared to healthy dogs and recombinant human ACE2 (rhACE2) alters relative concentrations of APs. ANIMALS: Forty‐nine dogs with and 34 dogs without heart disease. METHODS: Immunohistochemistry and assays for tissue and plasma ACE2 activity and equilibrium concentrations of plasma RAAS APs were performed. RESULTS: Immunolabeling for ACE2 was present in kidney and myocardial tissue. Median plasma ACE2 activity was significantly increased in dogs with congestive heart failure (CHF; 6.9 mU/mg; interquartile range [IQR], 5.1‐12.1) as compared to control (2.2 mU/mg; IQR, 1.8‐3.0; P = .0003). Plasma equilibrium analysis of RAAS APs identified significant increases in the median concentrations of beneficial APs, such as angiotensin 1‐7, in dogs with CHF (486.7 pg/mL; IQR, 214.2‐1168) as compared to those with preclinical disease (41.0 pg/mL; IQR, 27.4‐45.1; P < .0001) or control (11.4 pg/mL; IQR, 7.1‐25.3; P = .01). Incubation of plasma samples from dogs with CHF with rhACE2 increased beneficial APs, such as angiotensin 1‐9 (preincubation, 10.3 pg/mL; IQR, 4.4‐37.2; postincubation, 2431 pg/mL; IQR, 1355‐3037; P = .02), while simultaneously decreasing maladaptive APs, such as angiotensin II (preincubation, 53.4 pg/mL; IQR, 28.6‐226.4; postincubation, 2.4 pg/mL; IQR, 0.50‐5.8; P = .02). CONCLUSIONS AND CLINICAL IMPORTANCE: Recognition of the ACE2 system expands the conventional view of the RAAS in the dog and represents an important potential therapeutic target.
has issue date	2019-06-28(xsd:dateTime)
bibo:doi	10.1111/jvim.15548
bibo:pmid	31254308
has license	cc-by-nc
sha1sum (hex)	eaeab732c9c3e204526d8e1ea34cf40e7f37731f
schema:url	https://doi.org/10.1111/jvim.15548
resource representing a document's title	Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease
has PubMed Central identifier	PMC6639469
has PubMed identifier	31254308
schema:publication	J Vet Intern Med
resource representing a document's body	covid:eaeab732c9c3e204526d8e1ea34cf40e7f37731f#body_text
is schema:about of	named entity 'produces' covid:arg/eaeab732c9c3e204526d8e1ea34cf40e7f37731f named entity 'natriuretic' named entity 'angiotensin' named entity 'heart disease' named entity 'angiotensin-converting enzyme' named entity 'homologue' named entity 'peptides' named entity 'angiotensin' named entity 'angiotensin-converting enzyme 2' named entity 'cardiac diseases' named entity 'plasma' named entity 'ACE2' named entity 'RAAS' named entity 'kidney' named entity 'peptides' named entity 'extracellular space' named entity 'diuretic' named entity 'ACE2' named entity 'ectosomes' named entity 'ANOVA' named entity '60 minutes' named entity 'Institutional Animal Care and Use Committee' named entity 'urine' named entity 'ventricle' named entity 'substrate' named entity 'left atrium' named entity 'metalloproteinases' named entity 'tissue membrane' named entity 'kidney' named entity 'ACE inhibitors' named entity 'aldosterone' named entity 'biotin' named entity 'protein' named entity 'ACE2' named entity 'ACE2' named entity 'dog' named entity 'Venipuncture' named entity 'OS X' named entity 'kidney' named entity 'C-terminus' named entity 'aldosterone antagonists' named entity 'angiotensin' named entity 'IHC' named entity 'Kidney' named entity 'echocardiographic' named entity 'DCM' named entity 'Figure 8' named entity 'ACE' named entity 'Bonferroni correction' named entity 'renin' named entity 'ACE2' named entity 'positively correlated' named entity 'ACE2' named entity 'University of Pennsylvania' named entity 'amino acids' named entity 'University of Pennsylvania' named entity 'ACE2' named entity 'mice' named entity 'heart disease' named entity 'immunolabeling' named entity 'fluorometric assay' named entity 'California' named entity 'plasma' named entity 'heart disease' named entity 'angiotensin-converting enzyme 2' named entity 'vasodilatory' named entity 'CHF' named entity 'CHF' named entity 'RAAS' named entity 'CHF' named entity 'angiotensin-converting enzyme' named entity 'feedback loop'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software